Company Description: FELIQS is a clinical-ready stage company. The Company has a portfolio of two patent-protected drug product ophthalmology candidates: - Retinopathy of prematurity (ROP) – FLQ-101, a lipid peroxidation inhibitor repurposed to prevent ROP. FLQ-101 will be in Phase I dosing planned in the US in 2024. Successful submission of Orphan Drug Designation to FDA. - Age-related macular degeneration (AMD) – FLQ-104, a proprietary lipid peroxidation and ferroptosis inhibitor for earlier intervention to treat AMD. FLQ-104 is currently in the discovery stage in Japan and in the US. FELIQS identifies each developmental candidate through its proprietary screening platform, specifically targeting lipid peroxidation/ferroptosis. These candidates have demonstrated proven efficacy in past prospective clinical trials. Each developmental candidate offers an attractive value proposition in terms of safety and convenient route of administration (oral). FELIQS is actively advancing its pipelines into clinical development, backed by well-experienced academic and industrial advisors. We're initiating a Series A round targeting $20 million to initiate a clinical trial for ROP(FLQ-101), and preclinical research for FLQ-104. For this expansion of the future product portfolio and to prepare for a successful future M&A or NASDAQ IPO. We look for investors and partners to participate in the opportunity of this new and proprietary technology.